FDA Drug Program Leader Steps Down Amid Ongoing Agency Shake‑Ups

The Food and Drug Administration has announced that its chief drug official will leave her post, adding to a series of recent changes at the agency. Dr. Tracy Beth Hoeg, who has overseen investigations into antidepressants, COVID‑19 vaccines and other common medicines, will be replaced by Dr. Mike Davis, the current deputy director. Hoeg’s exit follows the resignation of FDA Commissioner Marty Makary earlier this week and the departure of vaccine chief Dr. Vinay Prasad last month, both after criticism from industry groups and the public. The agency also named Karim Mikhail to lead its vaccines division, a move that reflects the broader reshuffling of leadership. The agency’s top drug director is normally a seasoned career scientist, yet Hoeg rose quickly under Makary’s guidance. She began as his special assistant and was promoted to oversee the FDA’s largest center, responsible for most prescription and over‑the‑counter drugs. Her background is in sports medicine and public health, but she gained notoriety during the pandemic for opposing mask mandates, school closures and vaccine requirements.Hoeg has a history of public commentary that challenged mainstream views on COVID‑19 and other health policies. She co‑authored papers with colleagues who later joined the Trump administration, and she hosted a podcast that promoted disputed claims about mRNA vaccines. During her tenure at the FDA, she led reviews of injectable RSV treatments for children, antidepressants and COVID‑19 vaccines. One notable investigation involved a brief analysis that linked ten reported child deaths to COVID‑19 shots, without providing supporting data. The findings were circulated internally but never formally released, while the CDC and FDA have repeatedly stated that serious vaccine side effects are extremely rare. Hoeg also examined a petition to add new warnings about potential pregnancy risks from antidepressants, including the possibility of autism. In March she reportedly tried to bring the petition’s author into a senior advisory role at the FDA, raising concerns about conflicts of interest among staff. These developments highlight ongoing tensions within the agency as it balances regulatory duties, political pressures and scientific scrutiny. The FDA’s future direction will depend on how the new leadership navigates these challenges while maintaining public trust in drug safety.